We are live on ! Find out more
MRKR icon

Marker Therapeutics
MRKR

60 hedge funds and large institutions have $20.4M invested in Marker Therapeutics in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

13% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 16

3% more funds holding

Funds holding: 58 → 60 (+2)

0.1% less ownership

Funds ownership: 3.03% → 2.93% (-0.1%)

4% less capital invested

Capital invested by funds: $21.2M → $20.4M (-$800K)

Holders
60
Holders Change
+2
Holders Change %
+3.45%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
18
Reduced
16
Closed
6
Calls
$438K
Puts
–
Net Calls
+$438K
Net Calls Change
+$77K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$160K
2
Renaissance Technologies
Renaissance Technologies
New York
+$142K
3
GCP
GSA Capital Partners
United Kingdom
+$94.3K
4
JP Morgan Chase
JP Morgan Chase
New York
+$75.3K
5
VF
Virtu Financial
New York
+$52.8K

Top Sellers

Rank Fund Capital Flow
1
Russell Investments Group
Russell Investments Group
United Kingdom
-$298K
2
PPA
Parametric Portfolio Associates
Washington
-$179K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$101K
4
Wells Fargo
Wells Fargo
California
-$54K
5
WS
Wedbush Securities
California
-$40.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$44K +$47K +3,026 New
AllianceBernstein
27
AllianceBernstein
Tennessee
$43K – – –
Morgan Stanley
28
Morgan Stanley
New York
$43K +$41.2K +2,652 +692%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$41K +$43.6K +2,808 New
Goldman Sachs
30
Goldman Sachs
New York
$40K -$23.9K -1,538 -36%
PCA
31
Personal Capital Advisors
California
$37K – – –
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$37K +$5.18K +334 +15%
Bank of America
33
Bank of America
North Carolina
$37K +$8.52K +549 +26%
WC
34
Wexford Capital
Florida
$37K +$40.1K +2,586 New
HSBC Holdings
35
HSBC Holdings
United Kingdom
$33K +$1.21K +78 +4%
Deutsche Bank
36
Deutsche Bank
Germany
$31K +$4.27K +275 +14%
Millennium Management
37
Millennium Management
New York
$30K +$31.6K +2,036 New
MM
38
Meridian Management
Arkansas
$26K – – –
ISL
39
Ingalls & Snyder LLC
New York
$22K -$12K -770 -33%
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$20K – – –
US Bancorp
41
US Bancorp
Minnesota
$19K – – –
TRCT
42
Tower Research Capital (TRC)
New York
$18K -$32.8K -2,112 -63%
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$16K +$17K +1,093 New
AWP
44
Ascent Wealth Partners
New York
$15K – – –
UBS Group
45
UBS Group
Switzerland
$12K +$6.05K +390 +87%
APA
46
American Portfolios Advisors
New York
$10.4K +$6.68K +430 +150%
Bank of Montreal
47
Bank of Montreal
Ontario, Canada
$9K +$5.39K +347 +253%
Citigroup
48
Citigroup
New York
$8K +$6.37K +410 +289%
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$7.39K -$3.83K -247 -33%
Legal & General Group
50
Legal & General Group
United Kingdom
$5K – – –
1
2
3

MRKR Hedge Fund Activity: Q4 2020 in Review

60 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2020, worth a combined $20.4M — down 3.8% from $21.2M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new MRKR positions and 6 closed out — a net gain of 2 holders — while 18 added to existing stakes and 16 trimmed.

The largest buyer was BlackRock, adding an estimated $160K. The largest seller was Russell Investments Group, exiting entirely with an estimated $298K sold.

  • 60 institutional investors held Marker Therapeutics (MRKR) as of Q4 2020, up from 58 in Q3 2020.
  • Funds reported $20.4M of Marker Therapeutics stock for Q4 2020, down 3.8% quarter-over-quarter.
  • 8 funds opened new Marker Therapeutics positions in Q4 2020 and 6 closed out, a net change of +2 holders.
  • The largest Marker Therapeutics buyer in Q4 2020 was BlackRock, an estimated $160K added.
  • The largest Marker Therapeutics seller in Q4 2020 was Russell Investments Group, an estimated $298K sold.

Based on aggregated 13F filings for Q4 2020.